High-dimensional noise in large-scale loss-of-function screen data and barriers to data-science entry Large-scale loss-of-function screens using CRISPR or siRNA are core tools of network medicine for identifying essential target genes and biomarkers that determine the survival of specific cancer cell lineages. However, the gene dependency data for individual tumor cell lines (e.g., DepMap) and associated genomic metadata generated by these screens are organized as terabyte-scale unstructured matrices, making interpretation with a single linear model virtually impossible. Computing the accumulated genotype‑phenotype matrix requires advanced high-dimensional data‑science expertise and complex coding pipelines, creating a persistent technical bottleneck that prevents typical cancer biologists or clinicians from validating hypotheses in real time and leads to stagnant lead times.

Establishing the DepMine architecture: integration of complex cancer profiles and automation of Synthetic Lethality In this study we fully deployed the DepMine platform, a Python‑implemented computational algorithm toolkit, to eliminate computational barriers and enable rapid screening of hidden vulnerabilities within tumor heterogeneity. The team designed a computational framework that merges user‑specified point mutations, copy-number variations (CNV), and transcriptomic expression levels into a single multidimensional tensor, thereby precisely constructing so‑called “cancer profiles.” This in silico engine mathematically computes interaction weights across complex multivariate datasets and provides an intuitive interface that automatically scans for synthetic lethal relationships—selectively killing cancer cells harboring particular genetic alterations—without requiring explicit programming.

Derivation of optimized biomarker weighting and demonstration of clinical stratification By operating the constructed DepMine toolkit and finely refining the multivariate statistical significance between candidate target genes and cancer profiles, we identified optimal biomarker boundary conditions that are immediately applicable in the clinic. Gene dependency scores filtered in silico passed real‑time cross‑validation against patient‑derived cancer cell survival data, achieving a false‑positive screening rate below baseline. This constitutes a quantitative validation at the human tumor‑model level of the causal integrity between a cancer cell’s genetic scar and the cell‑death kinetics induced by removal of a specific gene.

Standardization of a precision oncology R&D platform and establishment of a next‑generation IND anticancer pipeline This bioinformatics software‑engineering white paper resets the standard for anticancer drug discovery from resource‑intensive manual bench screening to a “genome‑profile‑computational‑based programmable therapeutic target prediction infrastructure.” By converting user‑defined complex query matrices into real‑time analytical tensors, the lead time for validating false‑positive hypotheses in early drug development is dramatically compressed. The resulting open‑source pipeline data and open‑reading‑frame computational coefficients will serve as the computational backbone for pre‑calculating effective precision‑stratification thresholds in future global regulatory clinical programs, and will function as a master reference that exponentially shortens the IND approval timeline for next‑generation personalized natural‑product and nucleic‑acid‑based genomic therapeutics.